Addressing autoimmune diseases with engineered MSCs

As the cell and gene therapy field matures, both new and old approaches are being leveraged and combined to enable the field to expand into indications beyond oncology. In this interview, David McCall, Senior Editor, BioInsights, and Miguel Forte, CEO, Kiji Therapeutics; President, ISCT, discuss a novel engineered off-the-shelf approach leveraging that old warhorse of cell therapy, mesenchymal stem cells.

Please enter your email to access content Read now